CoChat

Azithromycin or montelukast as inhaled corticosteroid–sparing agents in moderate-to-severe childhood asthma study

Open access
Strunk, Robert C., Bacharier, Leonard B., Phillips, Brenda R., Szefler, Stanley J., Zeiger, Robert S., Chinchilli, Vernon M., Martinez, Fernando D., Lemanske, Robert F., Taussig, Lynn M., Mauger, David T., Morgan, Wayne J., Sorkness, Christine A., Paul, Ian M., Guilbert, Theresa, Krawiec, Marzena, Covar, Ronina, Larsen, Gary · 2008 · Journal of Allergy and Clinical Immunology
Cited by 134

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background Clinical trials in children with moderate to severe persistent asthma are limited. Objective To determine if azithromycin or montelukast are inhaled corticosteroid-sparing. Methods The budesonide dose [with salmeterol (50 mcg) twice daily] necessary to achieve control was determined in children 6–17 years of age with moderate to severe persistent asthma. After a budesonide-stable period of 6 weeks, children were randomized in a double-masked, parallel, multi-center study to receive once nightly azithromycin, montelukast, or matching placebos, plus the established controlling dose of budesonide (minimum 400 mcg BID) and salmeterol twice daily. Primary outcome was time from randomization to inadequate asthma control following sequential budesonide dose reduction. Results Of 292 children screened, only 55 were randomized. Inadequate adherence to study medication (n=80) and improved asthma control under close medical supervision (n=49) were the major reasons for randomization failure. A futility analysis was requested by the Data Safety Monitoring Board. In data available for analyses, no differences were noted for either treatment compared to placebo in time to inadequate control status (median, weeks (95% CL) azithromycin: 8.4 (4.3, 17.3), montelukast 13.9 (4.7, 20.6), placebo 19.1 (11.7, infinity)), with no difference between the groups (logrank test, p = 0.49). The futility analysis indicated that even if the planned sample size was reached, results of this negative study were unlikely to be different and the trial was prematurely terminated. Conclusion Based upon these results, neither azithromycin nor montelukast is likely to be an effective ICS-sparing alternative in children with moderate to severe persistent asthma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2008.09.028

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 134

Metadata

Authors
Strunk, R. C., Bacharier, L. B., Phillips, B. R., Szefler, S. J., Zeiger, R. S., Chinchilli, V. M., Martinez, F. D., Lemanske, R. F., Taussig, L. M., Mauger, D. T., Morgan, W. J., Sorkness, C. A., Paul, I. M., Guilbert, T., Krawiec, M., Covar, R., & Larsen, G.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2008-12
Volume
122
Issue
6
Pages
1138-1144.e4
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2037466531
Cited by
134
References
1
FWCI
8.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.